J. Karp

G. Rosner, M. Zahurak, Richard J. Jones, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Sorafenib is tolerable and improves clinical outcomes in patients with FLT3‐ITD acute myeloid leukemia prior to stem cell transplant and after relapse post‐transplant

B. Smith, J. Karp, K. Pratz, 2014, American journal of hematology.

A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias

M. McDevitt, M. Carducci, S. Baker, 2010, Leukemia.

In vivo cell growth and pharmacologic determinants of clinical response in acute myelogenous leukemia.

R. Donehower, J. Karp, P. Burke, 1989, Blood.

In vivo cell growth and pharmacologic determinants of clinical response in acute myelogenous leukemia.

R. Donehower, J. Karp, P. Burke, 1989, Blood.

An in vitro model to predict clinical response in adult acute myelogenous leukemia.

R. Donehower, J. Karp, P. Burke, 1987, Seminars in oncology.

Correlation of drug-perturbed marrow cell growth kinetics and intracellular 1-B-D-arabinofuranosylcytosine metabolism with clinical response in adult acute myelogenous leukemia.

R. Donehower, J. Karp, P. Burke, 1987, Blood.

Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia.

Stephen J. Morris, E. Estey, M. Andreeff, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

through recruiting c-FLIP in vivo binds to Fas and suppresses Fas-mediated apoptosis α PMLRAR

J. Karp, D. Hawke, A. Rezaeian, 2013 .

PMLRARα binds to Fas and suppresses Fas-mediated apoptosis through recruiting c-FLIP in vivo.

J. Karp, D. Hawke, A. Rezaeian, 2011, Blood.

Farnesyl transferase inhibitors in myeloid malignancies.

J. Karp, J. Lancet, 2003, Blood reviews.

Molecular therapeutics of myelodysplasia and myelodysplasia-related leukaemias

J. Karp, C. Sarkodee-Adoo, C. Sarkodee‐Adoo, 1999 .

Tipifarnib (ZARNESTRATM in Previously Untreated Poor-Risk AML of the Elderly: Updated Results of a Multicenter Phase 2 Trial.

P. Greenberg, J. Karp, J. Lancet, 2004 .

A rationale for sequential high-dose chemotherapy of leukemia timed to coincide with induced tumor proliferation.

J. Karp, P. Burke, W. Vaughan, 1980 .

A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response.

S. Akinaga, Y. Shiotsu, J. Cortes, 2009, Blood.

Intravenous administration of recombinant human granulocyte-macrophage colony-stimulating factor causes a cutaneous eruption.

J. Karp, P. Burke, A. Hood, 1991, Archives of dermatology.

Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia.

G. Rosner, L. Doyle, B. Smith, 2017, Leukemia research.

Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML.

G. Nybakken, M. Borowitz, B. Smith, 2012, Blood.

Acute progranulocytic leukaemia: A model for molecular medicine

J. Karp, C. Sarkodee-Adoo, 1999 .

Targeting the process of farynesylation for therapy of hematologic malignancies.

J. Karp, J. Lancet, 2005, Current molecular medicine.

Induction of acute lymphocytic leukemia differentiation by maintenance therapy

Richard J. Jones, B. Smith, J. Karp, 2007, Leukemia.

Cancer susceptibility genes and their potential implication regarding systemic therapy for early‐stage breast cancer

A. Wolff, J. Karp, 2016, Cancer.

Central Role of Fas-associated Death Domain Protein in Apoptosis Induction by the Mitogen-activated Protein Kinase Kinase Inhibitor CI-1040 (PD184352) in Acute Lymphocytic Leukemia Cells in Vitro*

J. Sebolt-Leopold, D. Loegering, J. Karp, 2003, Journal of Biological Chemistry.

myelogenous leukemia poor-risk and elderly patients with previously untreated acute A phase 2 study of the farnesyltransferase inhibitor tipifarnib in

P. Greenberg, J. Karp, S. Kaufmann, 2010 .

Trying to improve clinical outcome in AML: lessons from negative trials.

B. Smith, J. Karp, 2005, Leukemia research.

A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia.

M. Tan, J. Karp, T. Garimella, 2005, Leukemia research.

Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience.

L. Neumayer, R. Theriault, H. Rugo, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias.

E. Sausville, J. Karp, J. Trepel, 2007, Blood.

Potential role of tamoxifen in prevention of breast cancer.

B. Kramer, L. Ford, J. Karp, 1991, Journal of the National Cancer Institute.

Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse.

John Calvin Reed, S. Krajewski, J. Karp, 1998, Blood.

Farnesyltransferase inhibitors and myeloid malignancies: phase I evidence of Zarnestra activity in high-risk leukemias.

J. Karp, J. Lancet, J. Rosenblatt, 2002, Seminars in hematology.

Phase II study of SU5416—a small‐molecule, vascular endothelial growth factor tyrosine‐kinase receptor inhibitor—in patients with refractory myeloproliferative diseases

H. Kantarjian, G. Garcia-Manero, A. Stopeck, 2003, Cancer.

CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo

James M. Bogenberger, R. Mesa, K. Flatten, 2014, Haematologica.

Elevated lactate dehydrogenase (LDH) can be a marker of immune suppression in cancer: Interplay between hematologic and solid neoplastic clones and their microenvironments.

J. Karp, A. Emadi, Jennifer Ding, 2017, Cancer biomarkers : section A of Disease markers.

insights into the basis for cytotoxic response to FLT3 inhibitors Plasma inhibitory activity (PIA): A pharmacodynamic assay reveals

E. Estey, H. Kantarjian, I. Galinsky, 2013 .

Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors.

E. Estey, H. Kantarjian, D. DeAngelo, 2006, Blood.

Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia.

L. Zwelling, J. Karp, S. Kaufmann, 1994, Blood.

Quantitative analysis of breast cancer resistance protein and cellular resistance to flavopiridol in acute leukemia patients.

M. Tan, L. Doyle, J. Karp, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia

M. Maris, F. Ravandi, J. Karp, 2015, Haematologica.

Phase I and Pharmacologic Study of Infusional Topotecan and Carboplatin in Relapsed and Refractory Acute Leukemia

J. Sloan, D. Loegering, J. Karp, 2005, Clinical Cancer Research.

Risk assessment in human immunodeficiency virus-associated acute myeloid leukemia

J. Karp, J. Greer, M. Levis, 2012, Leukemia & lymphoma.

Phase I and pharmacodynamic study of taxol in refractory acute leukemias.

D. Ettinger, R. Donehower, J. Karp, 1989, Cancer research.

Genetics of donor cell leukemia in acute myelogenous leukemia and myelodysplastic syndrome

Catherine Lai, J. Karp, K. Doucette, 2021, Bone Marrow Transplantation.

Advances in therapeutic options for newly diagnosed, high-risk AML patients

Catherine Lai, J. Karp, K. Doucette, 2021, Therapeutic advances in hematology.

Pharmacology and toxicity of high-dose cytarabine by 72-hour continuous infusion.

R. Donehower, J. Karp, P. Burke, 1986, Cancer treatment reports.

Enhancement of drug cytotoxicity by recruitment of leukemic myeloblasts with humoral stimulation.

J. Karp, P. Burke, 1976, Cancer research.

Osteoblasts Protect AML Cells From SDF‐1‐Induced Apoptosis

A. V. van Wijnen, B. Smith, J. Karp, 2014, Journal of cellular biochemistry.

Development of Farnesyltransferase Inhibitors for Clinical Cancer Therapy: Focus on Hematologic Malignancies

J. Karp, J. Lancet, 2007, Cancer investigation.

Development of the farnesyltransferase inhibitor tipifarnib for therapy of hematologic malignancies.

J. Karp, J. Lancet, 2005, Future oncology.

A Prospective Study of Peritransplant Sorafenib for Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic Transplantation

G. Rosner, M. Zahurak, Richard J. Jones, 2020 .

Farnesyltransferase Inhibitors in Leukemia

J. Karp, J. Lancet, J. Rosenblatt, 2003 .

New agents in acute myeloid leukemia: Beyond cytarabine and anthracyclines

J. Karp, A. Fathi, 2009, Current oncology reports.

A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders.

M. Sznol, J. Karp, F. Giles, 2008, Leukemia research.

LYMPHOID NEOPLASIA 4EBP1/c-MYC/PUMA and NF- k B/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells

K. Flatten, B. Smith, J. Karp, 2016 .

Acquired genomic copy number aberrations and survival in adult acute myelogenous leukemia.

Kerby Shedden, Cheng Li, Judith Karp, 2010, Blood.

Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells.

Christopher G. Kanakry, C. Thoburn, C. Meyer, 2011, Blood.

Induction of programmed cell death in Kaposi's sarcoma cells by preparations of human chorionic gonadotropin.

A. Sabichi, J. Karp, R. Gallo, 1999, Journal of the National Cancer Institute.

Pre-radiation lymphocyte harvesting and post-radiation reinfusion in patients with newly diagnosed high grade gliomas

C. Drake, M. Golightly, J. Karp, 2015, Journal of Neuro-Oncology.

Exposure–Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies

J. Gobburu, J. Karp, M. Rudek, 2017, Clinical Cancer Research.

Exposure–ResponseofVeliparib to InformPhase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies

J. Gobburu, J. Karp, M. Rudek, 2017 .

Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia

J. Herman, M. McDevitt, B. Smith, 2010, Epigenetics.

A clinically relevant population of leukemic CD34 (cid:1) CD38 (cid:2) cells in acute myeloid leukemia

M. Borowitz, L. Morsberger, Richard J. Jones, 2012 .

Phase I Study of Flavopiridol in Combination with Imatinib Mesylate (STI571, Gleevec) in Bcr/Abl+ Hematological Malignancies.

John D. Roberts, B. Druker, S. Grant, 2005 .

Topoisomerase II levels during granulocytic maturation in vitro and in vivo.

L. Liu, M. Kastan, J. Karp, 1991, Cancer research.

A rationale for sequential high-dose chemotherapy of leukemia timed to coincide with induced tumor proliferation.

J. Karp, P. Burke, W. Vaughan, 1980, Blood.

Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies

John D. Roberts, S. Grant, J. Karp, 2012, Cancer Chemotherapy and Pharmacology.

Acute myelogenous leukemia

J. Karp, 2007 .

Risk-based classification of leukemia by cytogenetic and multiplex molecular methods: results from a multicenter validation study

J. Karp, E. Labourier, L. Brusca, 2012, Blood Cancer Journal.

Response to ‘comparison of “sequential” versus “standard” chemotherapy as re‐induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (aml): results of the uk medical research council aml‐r trial’

B. Smith, J. Karp, P. Burke, 2003, British journal of haematology.

Long chemotherapy‐free remissions after single‐cycle timed‐sequential chemotherapy for acute myelocytic leukemia

J. Karp, P. Burke, W. Vaughan, 1980, Cancer.

Association of acute myeloid leukemia’s most immature phenotype with risk groups and outcomes

G. Rosner, Y. Ning, L. Morsberger, 2016, Haematologica.

A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia.

Bob Löwenberg, Jason Gotlib, Yixin Wang, 2007, Blood.

Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia.

Yixin Wang, S. Malek, M. McDevitt, 2012, Blood.

Development of therapeutic agents for older patients with acute myelogenous leukemia.

C. Hourigan, J. Karp, 2010, Current opinion in investigational drugs.

Acute leukemia expressing the normal human hematopoietic stem cell membrane glycoprotein CD34 (MY10).

D. Weisenburger, W. Sanger, J. Karp, 1988, Leukemia.

Modifying risks of secondary leukemias: is drug scheduling important?

J. Karp, M. Smith, 1996, Journal of the National Cancer Institute.

Growth response of residual leukemia after initial drug therapy.

J. Karp, P. Burke, 1986, Cancer research.

Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse?

E. Estey, R. Gale, J. Karp, 2020, Leukemia.

Reason for CPXcitement in AML.

J. Karp, J. Zeidner, 2014, Blood.

Intermittent high-dose cyclophosphamide chemotherapy for small cell carcinoma of the lung.

D. Ettinger, J. Karp, H. Braine, 1978, Cancer treatment reports.

Relationship of the hematopoietic cycle to the combined activities of a stimulator and a short-lived inhibitor.

J. Karp, P. Burke, 1987, Blood.

inhibitor, in adults with refractory and relapsed acute leukemias Phase 1 and pharmacologic study of MS-275, a histone deacetylase

J. Karp, J. Trepel, A. Sparreboom, 2013 .

Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML).

G. Rosner, L. Doyle, B. Smith, 2018, Leukemia research.

A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia

G. Rosner, J. Herman, M. McDevitt, 2016, Clinical Cancer Research.

The state of the union on treatment of acute myeloid leukemia

J. Karp, A. Emadi, 2014, Leukemia & lymphoma.

Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias

M. McDevitt, K. Flatten, B. Smith, 2012, Clinical Cancer Research.

Phase I dose escalation trial of sorafenib as a single agent for adults with relapsed and refractory acute leukemias.

B. Smith, J. Karp, J. Wright, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SNS-595 Demonstrates Clinical Responses in a Phase 1 Study in Acute Leukemia.

H. Kantarjian, F. Ravandi, J. Karp, 2007 .

A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms

M. McDevitt, B. Smith, J. Karp, 2014, Haematologica.

Minimal Residual Disease in Acute Myeloid Leukemia

C. Hourigan, J. Karp, 2014 .

Combined Methyltransferase/Histone Deacetylase Inhibition with 5-Azacitidine and MS-275 in Patients with MDS, CMMoL and AML: Clinical Response, Histone Acetylation and DNA Damage.

J. Herman, S. Baylin, J. Licht, 2006 .

Topoisomerase II and the response to antileukemic therapy.

L. Zwelling, J. Karp, S. Kaufmann, 1998, Leukemia & lymphoma.

Changes in topoisomerase I levels and localization during myeloid maturation in vitro and in vivo.

J. Karp, S. Kaufmann, P. Burke, 1995, Cancer research.

Topoisomerase I 1 Levels and Drug Sensitivity in Adult Acute Myelogenous Leukemia

Leonard, Richard J. Jones, J. Karp, 2022 .

cyclophosphamide for adults with refractory acute leukemias A phase 1 clinical-laboratory study of clofarabine followed by

M. McDevitt, B. Smith, J. Karp, 2013 .

A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias.

M. McDevitt, B. Smith, J. Karp, 2007, Blood.

Influence of humoral regulators on proliferation and maturation of normal and leukemic cells.

J. Karp, P. Burke, 1976, Cancer research.

Effective chemotherapy of acute myelocytic leukemia occurring after alkylating agent or radiation therapy for prior malignancy.

J. Karp, P. Burke, W. Vaughan, 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ribonucleotide reductase: an old target with new potential.

B. Smith, J. Karp, 2003, Leukemia research.

Durable Treatment-Free Remission after High-Dose Cyclophosphamide Therapy for Previously Untreated Severe Aplastic Anemia

Richard J. Jones, B. Smith, J. Karp, 2001, Annals of Internal Medicine.

Population pharmacokinetics and site of action exposures of veliparib with topotecan plus carboplatin in patients with haematological malignancies

J. Gobburu, J. Karp, M. Rudek, 2017, British journal of clinical pharmacology.

Farnesyltransferase inhibitors (FTIs) in myeloid malignancies.

J. Karp, J. Lancet, 2004, Annals of hematology.

Phase I Trial of the Oral Poly (ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888, V) Combined Wtih Topoecan (T) and Carboplatin (C) for Adults with Relapsed and Refractory Acute Leukemias,

A. Chen, J. Karp, S. Kaufmann, 2010 .

mutation-dependent and -independent imatinib resistance Adaphostin-induced oxidative stress overcomes BCR/ABL

E. Sausville, Z. Estrov, K. Bhalla, 2013 .

Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance.

E. Sausville, Z. Estrov, K. Bhalla, 2006, Blood.

Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms

J. Herman, M. McDevitt, E. Swisher, 2016, Clinical Cancer Research.

Phase 1 dose‐escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemias

M. McDevitt, B. Smith, J. Karp, 2012, British journal of haematology.

CD30 in myeloid malignancies: hitting the bull's-eye with an available dart

J. Karp, A. Emadi, 2013, Leukemia & lymphoma.

Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome.

R. Arceci, M. McDevitt, J. Karp, 2003, Blood cells, molecules & diseases.

CXCR4 Chemokine Receptor Signaling Induces Apoptosis in Acute Myeloid Leukemia Cells via Regulation of the Bcl-2 Family Members Bcl-XL, Noxa, and Bak*

B. Smith, J. Karp, S. Kaufmann, 2013, The Journal of Biological Chemistry.

Leukemia Cells via Regulation of the Bcl-2 Induces Apoptosis in Acute Myeloid CXCR 4 Chemokine Receptor Signaling Molecular Bases of Disease :

B. Smith, J. Karp, S. Kaufmann, 2013 .

Immune Modulation with Pomalidomide after Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML)

B. Smith, J. Karp, M. Levis, 2015 .

Megestrol acetate v tamoxifen in advanced breast cancer: a phase III trial of the Piedmont Oncology Association (POA).

J. Karp, P. Burke, 1985 .

Acute leukemia.

J. Karp, 1997, International journal of oncology.

Addition of etoposide to initial therapy of adult acute lymphoblastic leukemia: a combined clinical and laboratory study.

J. Karp, S. Kaufmann, S. Gore, 1996, Leukemia & lymphoma.

The clinically relevant pharmacogenomic changes in acute myelogenous leukemia.

J. Karp, A. Emadi, 2012, Pharmacogenomics.

Leukemic Relapse Elevated Expression of the Apoptotic Regulator Mcl-1 at the Time of

John Calvin Reed, S. Krajewski, J. Karp, 2013 .

Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies.

J. Karp, 2001, Seminars in hematology.

A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia

J. Herman, M. McDevitt, A. Chen, 2016, Clinical Cancer Research.

Isokinetic Gradient Sedimentation of Hematopoietic Progenitor Cells

J. Karp, J. Spivak, 1987 .

Correlation of proliferative and clonogenic tumor cells in multiple myeloma.

J. Karp, P. Burke, R. Humphrey, 1984, Cancer research.

Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia

L. Zwelling, Richard J. Jones, J. Karp, 1994 .

The long road to a cure for acute myelocytic leukemia: from intensity to specificity.

J. Karp, W. Vaughan, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular pathogenesis and targets for therapy in myelodysplastic syndrome (MDS) and MDS‐related leukemias

J. Karp, 1998, Current opinion in oncology.

Progress in clinical chemoprevention.

V. Steele, E. Hawk, C. Boone, 1997, Seminars in oncology.

Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF.

Zhe Zhang, S. Piantadosi, J. Kowalski, 2011, Leukemia research.

Cures of leukemia with aggressive postremission treatment: an update of timed sequential therapy (Ac-D-Ac).

J. Karp, R. Geller, P. Burke, 1989, Leukemia.

Curing acute myelogenous leukemia: still a major challenge.

B. Smith, J. Karp, 2005, Leukemia research.

Escalation Trial of Clofarabine Followed by Escalating Dose of Fractionated Cyclophosphamide in Adults with Relapsed or Refractory Acute Leukemias

J. Karp, J. Greer, H. Carraway, 2011 .

Timed sequential therapy of human leukemia based upon the response of leukemic cells to humoral growth factors.

J. Karp, H. Braine, P. Burke, 1977, Cancer research.

Effects of Selective Checkpoint Kinase 1 Inhibition on Cytarabine Cytotoxicity in Acute Myelogenous Leukemia Cells In Vitro

Erin L. Schenk, K. Flatten, B. Smith, 2012, Clinical Cancer Research.

Cancer Therapy : Preclinical Effects of Selective Checkpoint Kinase 1 Inhibition on Cytarabine Cytotoxicity in Acute Myelogenous Leukemia Cells In Vitro

Erin L. Schenk, K. Flatten, B. Smith, 2012 .

Cure of acute myelocytic leukemia in adults: a reality.

J. Karp, R. Geller, P. Burke, 1990, Leukemia.

Epidemiology of Candida kefyr in Patients with Hematologic Malignancies

T. Perl, J. Karp, J. Staab, 2014, Journal of Clinical Microbiology.

Poly(ADP-ribose) Polymerase Inhibitors Sensitize Cancer Cells to Death Receptor-mediated Apoptosis by Enhancing Death Receptor Expression*

K. Flatten, B. Smith, J. Karp, 2014, The Journal of Biological Chemistry.

Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide.

D. Loegering, K. Flatten, N. T. Dai, 2009, Blood.

Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia

C. Hourigan, J. Karp, N. Ramos, 2015, Journal of clinical medicine.

Two-cycle timed-sequential chemotherapy for adult acute nonlymphocytic leukemia.

J. Karp, P. Burke, P. Burke, 1984, Blood.

Prevention and Treatment of Cancer-Related InfectionsPractice Guidelines in Oncology

R. Garzon, S. Seo, J. Montoya, 2012 .

J. Karp, R. Yarchoan, J. Pluda, 1996 .

Targeting TCTP with Sertraline and Thioridazine in Cancer Treatment.

F. André, R. Amson, A. Telerman, 2017, Results and problems in cell differentiation.

Endothelial expression of intercellular adhesion molecule (ICAM‐1) is unaffected by marrow aplasia‐inducing chemotherapy

J. Karp, P. Burke, A. Hood, 1991, Journal of cutaneous pathology.

Epidemiology, outcomes, and risk factors of invasive fungal infections in adult patients with acute myelogenous leukemia after induction chemotherapy.

Amanda Blackford, Judith Karp, Kieren A Marr, 2013, Diagnostic microbiology and infectious disease.

Phase I Clinical Trials in Acute Myeloid Leukemia: 23-Year Experience From Cancer Therapy Evaluation Program of the National Cancer Institute.

E. Dees, J. Karp, A. Blackford, 2016, Journal of the National Cancer Institute.

Cutaneous eruptions of lymphocyte recovery.

J. Karp, P. Burke, A. Hood, 1989, Archives of dermatology.

Acute leukemia: early recognition can spell survival.

J. Karp, P. Burke, W. Vaughan, 1981, Geriatrics.

Metabolic and electrochemical mechanisms of dimeric naphthoquinones cytotoxicity in breast cancer cells.

C. Dang, A. Ross, J. Karp, 2011, Bioorganic & medicinal chemistry.

Human histocompatibility antigens and survival in acute myelocytic leukemia

J. Karp, W. Bias, Maurie Markman, 1984, Cancer.

Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation

Michael A McDevitt, J. Herman, M. McDevitt, 2010, Leukemia & lymphoma.

NF1 Inactivation in Adult Acute Myelogenous Leukemia

Yang Liu, P. Ouillette, S. Malek, 2010, Clinical Cancer Research.

Inactivation in Adult Acute Myelogenous Leukemia

P. Ouillette, S. Malek, K. Shedden, 2010 .

JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained

D. Steensma, H. Powell, J. Karp, 2006, Leukemia.

Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy.

D. Venzon, S. Broder, J. Karp, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Timed sequential chemotherapy of cytoxan-refractory multiple myeloma with cytoxan and adriamycin based on induced tumor proliferation.

J. Karp, P. Burke, R. Humphrey, 1981, Blood.

Direct Relationship of Marrow Cell Growth and 1-/?-D-Arabinofuranosy Icytosine Metabolism1

R. Donehower, J. Karp, P. Burke, 2006 .

Induction of serum stimulation and plasma cell proliferation during chemotherapy of multiple myeloma.

J. Karp, P. Burke, R. Humphrey, 1977, Blood.

Chemotherapy of leukemia in mice, rats, and humans relating time of humoral stimulation, tumor growth, and clinical response.

J. Karp, P. Burke, W. Vaughan, 1981, Journal of the National Cancer Institute.

Phase Ib/II pharmacokinetic/pharmacodynamic (PK/PD) study of combination voreloxin and cytarabine in relapsed or refractory AML patients.

J. Karp, J. Lancet, L. Cripe, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution.

M. McDevitt, Richard J. Jones, B. Smith, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Expression of breast cancer resistance protein in blast cells from patients with acute leukemia

L. Doyle, J. Karp, D. Ross, 2000 .

Current status of clinical trials of farnesyltransferase inhibitors

J. Karp, S. Kaufmann, J. Lancet, 2001, Current opinion in oncology.

Human herpesvirus 8 K1-associated nuclear factor-kappa B-dependent promoter activity: role in Kaposi's sarcoma inflammation?

J. Karp, O. Prakash, S. Pati, 2000, Journal of the National Cancer Institute. Monographs.

A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia.

M. Borowitz, L. Morsberger, Richard J. Jones, 2012, Blood.

BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma.

A. K. Church, J. Cerhan, A. Feldman, 2015, Blood.

Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms.

M. Grever, J. Herman, S. Baylin, 2006, Cancer research.

Protein kinase Cbeta modulates ligand-induced cell surface death receptor accumulation: a mechanistic basis for enzastaurin-death ligand synergy.

D. Loegering, K. Flatten, Michael P Heldebrant, 2010, The Journal of biological chemistry.

Acute lymphoblastic leukemia and lymphoma in adults

J. Karp, H. Carraway, A. Advani, 2010 .

Constitutive BAK activation as a determinant of drug sensitivity in malignant lymphohematopoietic cells

J. Karp, S. Kaufmann, Haiming Dai, 2015, Genes & development.

Lessons from tumor reversion for cancer treatment

R. Amson, A. Telerman, J. Karp, 2013, Current opinion in oncology.

Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies.

Wei Zhang, Jeanne Kowalski, Hua-Ling Tsai, 2009, Cancer research.

Epigenetic and genetic loss of Hic1 function accentuates the role of p53 in tumorigenesis.

C. Zahnow, S. Baylin, M. Ladanyi, 2004, Cancer cell.

Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome

M. L. Beau, M. McDevitt, J. Karp, 2002, Nature Genetics.

The secondary leukemias: challenges and research directions.

J. Karp, M. Smith, R. McCaffrey, 1996, Journal of the National Cancer Institute.

New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid leukemia.

M. McDevitt, C. O'keefe, L. Gondek, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

prognostic markers in acute leukemia Evaluation of Apaf-1 and procaspases-2, -3, -7, -8, and -9 as potential

Y. Lazebnik, John Calvin Reed, S. Krajewski, 2013 .

Evaluation of Apaf-1 and procaspases-2, -3, -7, -8, and -9 as potential prognostic markers in acute leukemia.

Y. Lazebnik, John Calvin Reed, S. Krajewski, 2000, Blood.

Leukemic retinopathy. Relationship between fundus lesions and hematologic parameters at diagnosis.

D. Guyer, A. Schachat, J. Karp, 1989, Ophthalmology.

Ophthalmic manifestations of leukemia.

D. Guyer, A. Schachat, J. Karp, 1989, Archives of ophthalmology.

Overcoming drug resistance: targeting more than one site.

J. Karp, B. Mookerjee, 2002, Leukemia research.

What are the endpoints of therapy for acute leukemias? Old definitions and new challenges.

B. Smith, J. Karp, 2009, Clinical lymphoma & myeloma.

Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies.

M. Sznol, J. Karp, J. Greer, 2007, Leukemia research.

The impact of biology on the treatment of secondary AML.

J. Karp, I. Gojo, 2001, Cancer treatment and research.

Factors affecting survival of patients with acute myelocytic leukemia presenting with high wbc counts.

A. Kimball, J. Karp, P. Burke, 1981, Cancer treatment reports.

MLN4924 induces Noxa upregulation in acute myelogenous leukemia and synergizes with Bcl-2 inhibitors

B. Smith, J. Karp, S. Kaufmann, 2015, Cell Death and Differentiation.

Regulation of leukemic cell adhesion, proliferation, and survival by beta-catenin.

Su-Jae Lee, J. Rubin, Sang-Gu Hwang, 2002, Blood.

Asynchronous Antigen Expression in B Lineage Acute Lymphoblastic Leukemia

M. Borowitz, J. Karp, C. Civin, 1988 .

Asynchronous antigen expression in B lineage acute lymphoblastic leukemia.

M. Borowitz, J. Karp, C. Civin, 1988, Blood.

Timed-Sequential Chemotherapy for Adult Acute Nonlymphocytic Leukemia

J. Karp, P. Burke, W. Vaughan, 2011 .

MCL-1 as a Buffer for Proapoptotic BCL-2 Family Members during TRAIL-induced Apoptosis

David Loegering, Sun-Hee Lee, Chunrong Yu, 2007, Journal of Biological Chemistry.

Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia.

K. Cowan, J. Karp, S. Kaufmann, 1995, Blood.

Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemia.

B. Smith, J. Karp, J. Trepel, 2021, Leukemia research.

Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer

E. Sausville, J. Karp, A. Sparreboom, 2006, Investigational New Drugs.

Expression of breast cancer resistance protein in blast cells from patients with acute leukemia.

L. Doyle, J. Karp, D. Ross, 2000, Blood.

Histone deacetylase inhibitor pharmacodynamic analysis by multiparameter flow cytometry.

E. Sausville, W. Telford, J. Karp, 2005, Annals of clinical and laboratory science.

Clinical and pharmacologic study of tributyrin: an oral butyrate prodrug

M. Edelman, J. Karp, J. Trepel, 2003, Cancer Chemotherapy and Pharmacology.

Exposure–Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients

V. Ivaturi, J. Gobburu, L. Doyle, 2017, Clinical Cancer Research.

Sequential Flavopiridol, Cytosine Arabinoside, and Mitoxantrone: A Phase II Trial in Adults with Poor-Risk Acute Myelogenous Leukemia

Richard J. Jones, B. Smith, J. Karp, 2007, Clinical Cancer Research.

Treatment strategies for hematological malignancies: Impact on host defenses and infection risk

J. Karp, I. Gojo, W. Merz, 2003 .

A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia.

P. Greenberg, Y. Park, J. Karp, 2007, Blood.

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.

J. Karp, S. Kaufmann, J. Wright, 2001, Blood.

Targeting FGFR1 to suppress leukemogenesis in syndromic and de novo AML in murine models

S. Malek, J. Karp, J. Cowell, 2016, Oncotarget.

A phase II study of timed sequential therapy of acute myelogenous leukemia (AML) for patients over the age of 60: two cycle timed sequential therapy with topotecan, ara-C and mitoxantrone in adults with poor-risk AML.

J. Karp, I. Gojo, Chuanfa Guo, 2004, Leukemia research.

cytotoxicity in human leukemia cells Involvement of reactive oxygen species in adaphostin-induced

E. Sausville, D. Loegering, J. Karp, 2013 .

Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells.

E. Sausville, D. Loegering, J. Karp, 2003, Blood.

A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease

M. Carroll, M. Tallman, J. Karp, 2018, American journal of hematology.

New Strategies in Acute Myelogenous Leukemia: Leukemogenesis and Personalized Medicine

J. Karp, I. Gojo, 2014, Clinical Cancer Research.

Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial.

R. Larson, F. Appelbaum, M. Tallman, 2021, Leukemia research.

Long-term follow-up of intensive ara-C-based chemotherapy followed by bone marrow transplantation for adult acute lymphoblastic leukemia: impact of induction Ara-C dose and post-remission therapy.

S. Piantadosi, J. Karp, S. Kaufmann, 2002, Leukemia research.

Prognostic importance of immunophenotyping in adults with acute myelocytic leukaemia: the significance of the stem‐cell glycoprotein CD34 (My 10)

S. Piantadosi, M. Zahurak, J. Karp, 1990, British journal of haematology.

A two-step timed sequential treatment for acute myelocytic leukemia.

M. Zahurak, J. Karp, R. Tucker, 1989, Blood.

New considerations in the design of clinical trials for the treatment of acute leukemia.

C. Hourigan, J. Karp, 2011, Clinical investigation.

Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells

A. Oberg, F. Sinicrope, D. Loegering, 2014, Haematologica.

The relationship between humoral stimulating activity and colony stimulating factor.

J. Karp, J. H. Shaper, R. Shadduck, 1983, Experimental hematology.

Cell microarray platform for anticancer drug development

E. Sausville, W. Telford, S. Hewitt, 2007 .

Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia.

J. Karp, J. Zeidner, 2015, Leukemia research.

Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia

G. Rosner, L. Doyle, B. Smith, 2015, Haematologica.

The molecular pathogenesis of treatment-induced (secondary) leukemias: foundations for treatment and prevention.

J. Karp, M. Smith, 1997, Seminars in oncology.

Genomic Mechanisms of p210BCR-ABL Signaling

J. Karp, S. Kaufmann, A. Fields, 2004, Journal of Biological Chemistry.

Fluorescent in situ hybridization (FISH) in bone marrow and peripheral blood of leukemia patients: implications for occupational surveillance.

M. McDevitt, J. Karp, M. McDiarmid, 2007, Mutation research.

Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro.

D. Loegering, B. Smith, J. Karp, 2009, Cancer research.

Targeting Vascular Endothelial Growth Factor for Relapsed and Refractory Adult Acute Myelogenous Leukemias

D. Qian, J. Karp, Helen H. W. Chen, 2004, Clinical Cancer Research.

SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes.

H. Kantarjian, A. Stopeck, J. Cortes, 2003, Blood.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

inhibitor tipifarnib in acute myeloid leukemia A 2-gene classifier for predicting response to the farnesyltransferase

Yixin Wang, P. Greenberg, R. Stone, 2008 .

Effects of rhGM-CSF on intracellular ara-C pharmacology in vitro in acute myelocytic leukemia: comparability with drug-induced humoral stimulatory activity.

R. Donehower, J. Karp, P. Burke, 1990, Leukemia.

Protein expression of PDZ-binding kinase is up-regulated in hematologic malignancies and strongly down-regulated during terminal differentiation of HL-60 leukemic cells.

J. Karp, M. Tidwell, A. Rapoport, 2004, Blood cells, molecules & diseases.

New agents in the treatment of acute myeloid leukemia: a snapshot of signal transduction modulation.

B. Smith, J. Karp, T. Bao, 2005, Clinical advances in hematology & oncology : H&O.

Exploiting cellular pathways to develop new treatment strategies for AML.

S. Grant, J. Karp, A. Fathi, 2010, Cancer treatment reviews.

KLFs and ATRA-induced differentiation: new pathways for exploitation.

J. Karp, F. Rassool, 2011, Leukemia research.

Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDS

H. Hackl, L. Gondek, J. Karp, 2020, Leukemia.

Analysis of the relationship between Scl transcription factor complex protein expression patterns and the effects of LiCl on ATRA-induced differentiation in blast cells from patients with acute myeloid leukemia.

A. Sartorelli, J. Karp, K. Holtz, 2004, Leukemia research.

Assessment of Drug Sensitivity in Hematopoietic Stem and Progenitor Cells from Acute Myelogenous Leukemia and Myelodysplastic Syndrome Ex Vivo

B. Smith, J. Karp, S. Kaufmann, 2016, Stem cells translational medicine.

Poly(ADP-ribose) polymerase inhibitor CEP-8983 synergizes with bendamustine in chronic lymphocytic leukemia cells in vitro.

J. Herman, M. McDevitt, J. Karp, 2014, Leukemia research.

Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia.

A. Stopeck, J. Cherrington, J. Karp, 2004, Leukemia research.

Performance and clinical evaluation of a sensitive multiplex assay for the rapid detection of common NPM1 mutations.

Keith D Jackson, J. Karp, E. Labourier, 2010, The Journal of molecular diagnostics : JMD.

Interleukin 2 and granulocyte-macrophage colony-stimulating factor induce a perivascular lymphocytic infiltrate in a skin explant model.

J. Karp, P. Burke, G. Vogelsang, 1991, Archives of dermatology.

Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy.

H. Hackl, J. Karp, A. Blackford, 2018, JCI insight.

Should MAGE be the rage in myeloma

C. Huff, J. Karp, 2005 .

The spectrum of genetic mutations in myelodysplastic syndrome: Should we update prognostication?

Catherine Lai, J. Karp, Michael R. Cook, 2021, EJHaem.

CCR New Strategies New Strategies in Acute Myelogenous Leukemia : Leukemogenesis and Personalized Medicine

J. Karp, I. Gojo, 2014 .

Timed sequential therapy of acute myelogenous leukemia in adults: a phase II study of retinoids in combination with the sequential administration of cytosine arabinoside, idarubicin and etoposide.

J. Karp, M. Tidwell, A. Rapoport, 2003, Leukemia research.

Drug induced host factors which stimulate growth of residual leukemia in Lewis x Brown Norway F1 (LEW-BN) rats.

J. Karp, P. Burke, P. Saylor, 1986, Cancer research.

Increased tumor growth and drug uptake predicts for response to continuous infusion high-dose cytarabine.

J. Karp, P. Burke, 1985, Seminars in oncology.

Recruitment of quiescent tumor by humoral stimulatory activity: requirements for successful chemotherapy.

J. Karp, P. Burke, W. Vaughan, 1982, Blood cells.

Patients with FLT3/ITD AML May Benefit From Allogeneic Transplant In First Remission: Outcomes From a Consecutive Series of Patients at a Single Institution

M. McDevitt, J. Kowalski, Richard J. Jones, 2010 .

Direct relationship of marrow cell growth and 1-beta-D-arabinofuranosylcytosine metabolism.

R. Donehower, J. Karp, P. Burke, 1984, Cancer research.

Timed sequential therapy for acute myelogenous leukemia: Results of a retrospective study of 301 patients and review of the literature.

R. Varadhan, M. McDevitt, B. Smith, 2017, Leukemia research.

Hypoalbuminemia as a prognostic biomarker for higher mortality and treatment complications in acute myeloid leukemia

Catherine Lai, J. Karp, Jaeil Ahn, 2021, Hematological oncology.

Tipifarnib (Zarnestra, R115777) as Maintenance Therapy for Adults in Complete Remission (CR) Following Induction and Consolidation Therapies for Poor-Risk Acute Myelogenous Leukemia (AML): A Phase II Trial.

B. Smith, J. Karp, J. Greer, 2005 .

Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia

J. Karp, J. Lancet, 2008, Biologics : targets & therapy.

Phase II Trial of Tipifarnib as Maintenance Therapy in First Complete Remission in Adults with Acute Myelogenous Leukemia and Poor-Risk Features

B. Smith, J. Karp, J. Lancet, 2008, Clinical Cancer Research.

Phase II Trialof Tipifarnib asMaintenanceTherapy in First Complete Remission inAdultswithAcuteMyelogenous Leukemia andPoor-Risk Features

B. Smith, J. Karp, J. Lancet, 2008 .

A phase II study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia

P. Greenberg, Y. Park, J. Karp, 2006 .

Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia.

G. Mufti, H. Kantarjian, F. Ravandi, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Durable molecular remissions with a single cycle of timed sequential consolidation chemotherapy in acute promyelocytic leukemia

M. Grever, S. Piantadosi, W. Stock, 2005, American journal of hematology.

Precision medicine for acute myeloid leukemia

Catherine Lai, C. Hourigan, J. Karp, 2016, Expert review of hematology.

Active Oral Regimen for Elderly Adults with Newly Diagnosed Acute Myelogenous Leukemia (AML): Phase I Trial of Oral Tipifarnib (T) Combined with Oral Etoposide (E) for Adults ≥Age 70 Who Are Not Candidates for Traditional Cytotoxic Chemotherapy (TCC).

S. Malek, B. Smith, J. Karp, 2006 .

Comparison of Survival Times after Administration of Tipifarnib or Ara-C-Containing Therapy, to Older Patients with Newly-Diagnosed Acute Myeloid Leukemia.

P. Thall, E. Estey, J. Karp, 2006 .

Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia

Yixin Wang, D. Atkins, J. Karp, 2004, BMC Cancer.

Pharmacokinetic and Pharmacodynamic Studies of Lestaurtinib (CEP-701) and PKC-412: Cytotoxicity Is Often Dependent on Non-FLT3-Mediated Effects.

E. Estey, H. Kantarjian, R. Stone, 2005 .

Management of infectious complications of acute leukemia and antileukemia therapy.

J. Karp, W. Merz, J. Dick, 1990, Oncology.

4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells.

K. Flatten, B. Smith, J. Karp, 2016, Blood.

Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies.

K. Flatten, B. Smith, J. Karp, 2012, Blood.

Abstract S3-5: Myelodysplatic syndrome and/or acute myelogenous leukemia (MDS and/or AML) after a breast cancer diagnosis: the National Comprehensive Cancer Network (NCCN) experience.

L. Neumayer, A. Wolff, J. Weeks, 2012 .

CDK2-Mediated Upregulation of TNFα as a Mechanism of Selective Cytotoxicity in Acute Leukemia

Hu Li, K. Flatten, B. Smith, 2021, Cancer Research.

A Phase I Dose Escalation Study of KW-2449, An Oral Multi-Kinase Inhibitor against FLT3, Abl, FGFR1 and Aurora in Patients with Relapsed/Refractory AML, ALL and MDS or Resistant/Intolerant CML

S. Akinaga, H. Kantarjian, J. Cortes, 2008 .

Optimizing the dose and schedule of KW-2449, FLT3/Aurora inhibitor, through analysis of in vivo target inhibition

S. Akinaga, Y. Shiotsu, J. Karp, 2008 .

Acute leukemia: Mechanisms of cell survival as targets for therapy (review)

J. Karp, 1997 .

CLORETAZINE™ (VNP40101M) Is Active in Elderly Untreated Poor Risk Patients with Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS).

G. Mufti, J. Karp, S. O'brien, 2005 .

A rapid and sensitive method for determination of veliparib (ABT-888), in human plasma, bone marrow cells and supernatant by using LC/MS/MS.

J. Karp, M. Rudek, Ming Zhao, 2010, Journal of pharmaceutical and biomedical analysis.

Insulin Receptor A and IGF-IR in AML – Response

J. Karp, C. Erlichman, S. Kaufmann, 2010 .

Population pharmacokinetics and exposure–response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias

A. Chen, J. Gobburu, J. Karp, 2018, Cancer Chemotherapy and Pharmacology.

Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia

D. Steensma, R. Mesa, D. Loegering, 2011, Haematologica.

Systematic review and meta-analysis: Prognostic impact of time from diagnosis to treatment in patients with acute myeloid leukemia.

Valeriy R. Korostyshevskiy, J. Karp, Catherine Lai, 2023, Cancer.

Prognostic Impact of Secondary Versus De Novo Ontogeny in Acute Myeloid Leukemia (AML) Is Predominantly Accounted for By the European Leukemianet (ELN) 2022 Risk Classification

E. Estey, C. Hourigan, J. Karp, 2022, Blood.

Phase 2 Trial of the Farnesyltransferase Inhibitor Tipifarnib in Previously Untreated Older Adults with AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio

J. Karp, S. Kaufmann, J. Lancet, 2012 .

Therapy-related acute leukemia.

J. Karp, C. Sarkodee-Adoo, 2000, Clinics in Laboratory Medicine.

Randomized multicenter phase II trial of timed-sequential therapy with flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus “7+3” for adults with newly diagnosed acute myeloid leukemia (AML).

G. Rosner, J. Cain, L. Doyle, 2014 .

myeloid leukemia cells in acute - CD38 + A clinically relevant population of leukemic CD34

M. Borowitz, B. Smith, J. Karp, 2014 .

A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia.

H. Kantarjian, S. Verstovsek, J. Karp, 2006, Leukemia research.

BP1, a new homeobox gene, is frequently expressed in acute leukemias

F. Behm, S. Raimondi, B. Smith, 2000, Leukemia.

Postleukemic dysmyelopoiesis

J. Armitage, S. Patil, K. Foucar, 1983, American journal of hematology.

Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia : a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib ( R 115777 , Zarnestra ) combined with etoposide

D. Loegering, K. Flatten, N. T. Dai, 2008 .

An approach to intensive antileukemia therapy in patients with previous invasive aspergillosis.

J. Karp, J. Karp, P. Burch, 1988, The American journal of medicine.

Invasive pulmonary aspergillosis in acute leukemia. The contribution of CT to early diagnosis and aggressive management.

E. Fishman, E. Zerhouni, S. Siegelman, 1987, Chest.

Prognostic impact of secondary versus de novo ontogeny in acute myeloid leukemia is accounted for by the European LeukemiaNet 2022 risk classification

E. Estey, C. Hourigan, J. Karp, 2023, Leukemia.

A Comprehensive Assessment of Phase 1 Clinical Trials in Acute Myeloid Leukemia

J. Karp, A. Blackford, S. Ivy, 2014 .

Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine

R. Mesa, D. Loegering, H. Powell, 2005 .

Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies.

K. Flatten, J. Karp, S. Kaufmann, 2012, Blood.

D. Loegering, K. Flatten, J. Karp, 2009, Blood.

What are the endpoints of therapy for acute leukemias? Old definitions and new challenges.

B. Smith, J. Karp, 2009, Clinical lymphoma & myeloma.

Association of acute myeloid leukemia’s most immature phenotype with risk groups and outcomes

G. Rosner, Y. Ning, L. Morsberger, 2016, Haematologica.

NF1 Inactivation in Adult Acute Myelogenous Leukemia

Yang Liu, P. Ouillette, S. Malek, 2010, Clinical Cancer Research.

Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy.

H. Hackl, J. Karp, A. Blackford, 2018, JCI insight.

Personalized therapy for acute myeloid leukemia.

C. Hourigan, J. Karp, 2013, Cancer discovery.

IN THE SPOTLIGHT Personalized Therapy for Acute Myeloid Leukemia

C. Hourigan, J. Karp, 2013 .

Randomized Phase II Study of Two Schedules of Flavopiridol (Alvocidib, F) Given as Timed Sequential Therapy (TST) Wtih Ara-C and Mitoxantrone (FLAM) for Adults with Newly Diagnosed, Poor-Risk Acute Myelogenous Leukemia (AML)

E. Estey, L. Doyle, B. Smith, 2010 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, David M. Schauder, 2016, Journal for ImmunoTherapy of Cancer.

A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms

M. McDevitt, B. Smith, J. Karp, 2014, Haematologica.

Performance and clinical evaluation of a sensitive multiplex assay for the rapid detection of common NPM1 mutations.

Keith D Jackson, J. Karp, E. Labourier, 2010, The Journal of molecular diagnostics : JMD.